Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
- 1 November 2007
- Vol. 25 (49) , 8326-8337
- https://doi.org/10.1016/j.vaccine.2007.09.066
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Healthcare Costs of Acute and Chronic Pain Associated with a Diagnosis of Herpes ZosterJournal of the American Geriatrics Society, 2007
- Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsClinical Infectious Diseases, 2007
- Acute/Subacute Herpes ZosterPharmacoEconomics, 2007
- Priorities Among Effective Clinical Preventive Services: MethodsAmerican Journal of Preventive Medicine, 2006
- Pain, Medication Use, and Health-Related Quality of Life in Older Persons With Postherpetic Neuralgia: Results From a Population-Based SurveyThe Journal of Pain, 2005
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Treatment and Prevention of Postherpetic NeuralgiaClinical Infectious Diseases, 2003
- Epidemiology of varicella-zoster virus in England and WalesJournal of Medical Virology, 2003
- A study of shingles and the development of postherpetic neuralgia in East LondonJournal of Medical Virology, 2003
- The Cost of Treatment for Post-Herpetic Neuralgia in the UKPharmacoEconomics, 1994